Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8131 to 8145 of 9042 results

  1. Optical Coherence Tomography to guide percutaneous coronary intervention

    In development Reference number: GID-IPG10394 Expected publication date: TBC

  2. Pegcetacoplan for amyotrophic lateral sclerosis [TSID10594]

    In development Reference number: GID-TA11310 Expected publication date: TBC

  3. Tolebrutinib for treating primary progressive multiple sclerosis [ID6574]

    In development Reference number: GID-TA11762 Expected publication date:  28 July 2025

  4. Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]

    Discontinued Reference number: GID-TA11442

  5. Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]

    In development Reference number: GID-TA11441 Expected publication date: TBC

  6. Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer [TSID10701]

    In development Reference number: GID-TA11157 Expected publication date: TBC

  7. Superior rectal artery embolisation for haemorrhoids

    Discontinued Reference number: GID-IPG10417

  8. Suspected cancer update

    In development Reference number: GID-QS10176 Expected publication date: TBC

  9. Deucravacitinib for treating active psoriatic arthritis [ID6561]

    In development Reference number: GID-TA11510 Expected publication date: TBC

  10. L-Dex U400 for lymphoedema after breast cancer treatment (MIB111)

    April 2026: This Medtech innovation briefing has been withdrawn because the L-Dex U400 device is no longer available in the UK.

  11. Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072]

    In development Reference number: GID-TA10960 Expected publication date: TBC

  12. Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]

    In development Reference number: GID-TA11627 Expected publication date: TBC

  13. Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]

    Discontinued Reference number: GID-TA11009

  14. Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over [TSID12091]

    In development Reference number: GID-TA11679 Expected publication date: TBC

  15. Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]

    In development Reference number: GID-TA11750 Expected publication date: TBC